<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234349</url>
  </required_header>
  <id_info>
    <org_study_id>2012.768</org_study_id>
    <secondary_id>2012-A01517-36</secondary_id>
    <nct_id>NCT02234349</nct_id>
  </id_info>
  <brief_title>Bile Acids and Incretins in Pancreas Kidney Transplant Patients</brief_title>
  <acronym>ITABI</acronym>
  <official_title>Impact of Duodena-pancreatic Transplantation on Bile Acids and Incretins Metabolism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreas Kidney Transplantation (PKT) is the prominent treatment for type 1 diabetic patients
      with chronic kidney disease and improves patients' outcome. However, in spite of an optimized
      systemic insulin substitution, altered glucose metabolism and beta cell function are reported
      in these patients. The mechanisms behind these abnormalities are still unclear.
      Duodena-pancreatic anastomosis is performed in a heterotopic site (ileum) and thus could
      change physical and chemical properties of intestinal secretions, gut flora, as well as
      intestinal permeability. The effect of this procedure on gut derived metabolic factors, the
      enterohepatic cycle of bile acids, incretin secretion and intestinal flora have never been
      studied. This pilot prospective, study is aimed to evaluate the modification of bile acids
      concentrations and composition in PKT subjects, and the impact in glucose and incretin
      metabolism (measured by oral glucose tolerance test) one year after transplantation. The
      results will be compared to those of kidney transplant patients and control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bile acids concentrations</measure>
    <time_frame>One year after transplantation</time_frame>
    <description>Plasmatic bile acids concentration will be measured in serum by biochemical analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bile acids composition</measure>
    <time_frame>One year after transplantation</time_frame>
    <description>Plasmatic bile acids composition will be assessed in serum by gas chromatography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between bile acid modifications and Oral Glucose Tolerance test (OGT) measures</measure>
    <time_frame>One year after transplantation</time_frame>
    <description>OGT will be performed in all subjects. Data on insulin sensitivity and secretion, Glucagon-Like Peptide 1 (GLP-1) and fibroblast growth factor-19 will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Pancreas-Kidney Transplantation (PKT) on LipoPolySaccharides (LPS)</measure>
    <time_frame>One year after transplantation</time_frame>
    <description>LPS level will be measured before transplantation and one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of PKT on intestinal flora</measure>
    <time_frame>One year</time_frame>
    <description>Gut microbiota will be analysed before and after transplantation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreas-kidney Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>pancreas kidney transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pancreas kidney transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>kidney transplant subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with kidney transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreas kidney transplantation</intervention_name>
    <arm_group_label>pancreas kidney transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>kidney transplantation</intervention_name>
    <arm_group_label>kidney transplant subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients :

          -  BMI &lt;30 kg/m2

          -  Candidate for a first kidney transplant with a donor without the United Network for
             Organ Sharing (UNOS) criteria of extended donors and including living donors and
             pancreas-kidney donors (duodena-pancreas with ileal anastomosis and systemic drainage)

          -  Patients with conventional immunosuppression (maintenance with steroids, Tacrolimus
             and Mycophenolate Mofetil

          -  Willing and able to give informed consent

        Control subjects :

          -  Potential living kidney donor

        Exclusion Criteria:

          -  Subjects with a history of colectomy, gut resection or cholecystectomy

          -  For women : pregnancy

          -  Type 2 diabetes

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fitsum GUEBRE-EGZIABHER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Edourad Herriot - Pavillon P</name>
      <address>
        <city>LYON cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bile acids</keyword>
  <keyword>pancreas kidney transplantation</keyword>
  <keyword>incretins</keyword>
  <keyword>intestinal flora</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

